Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2083-2090

  Rusthoven, J J ^a   Quirt, I C ^a   Iscoe, N A ^a   McCulloch, P B ^a   James, K W ^a   Lohmann, R C ^a   Jensen, J ^a   Burdette Radoux, S ^a   Bodurtha, A J ^a   Silver, H K ^a   Verma, S ^a   Armitage, G R ^a   Zee, B ^a   Bennett, K ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; TAMOXIFEN; TAMOXIFEN CITRATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MELANOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 8944261598     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2083     Document Type: Article

References (34)

1. Comis RL: DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep 60:165-176, 1976
2. Costanzi JJ: DTIC (NSC-45388) studies in the Southwest Oncology Group. Cancer Treat Rep 60:189-192, 1976
3. Pritchard KI, Quirt IC, Cowan DH, et al: DTIC therapy in metastatic melanoma: A simplified dose schedule. Cancer Treat Rep 64:1123-1126, 1981
4. Bellet RE, Mastrangelo MJ, Laucius JF, et al: Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic melanoma. Cancer Treat Rep 60:595-600, 1976
5. Hill GJ, Krementz ET, Hill HZ: Dimethyl triazenoimidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy. Cancer 53:1299-1305,1984
6. Sadoff L, Winkley J, Tyson S: Is malignant melanoma an endocrine-dependent tumour? The possible adverse effect of estrogen. Oncology 27:244-257, 1973
7. Nesbit RA, Woods RL, Tattersall MH, et al: Tamoxifen in malignant melanoma. N Engl J Med 301:1241, 1979 (letter)
8. Reimer RR, Costanzi J, Fabian C: Southwest Oncology Group experience with tamoxifen in metastatic melanoma. Cancer Treat Rep 66:1680-1681, 1982
9. Masiel A, Buttrick P, Bitran J: Tamoxifen in the treatment of malignant melanoma. Cancer Treat Rep 65:531-532, 1981
10. Creagan ET, Ingle JN, Green SJ, et al: Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep 64:199-201, 1980
11. Rümke P, Kleeberg UR, MacKie RM, et al: Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II of the EORTC malignant melanoma cooperative group. Melanoma Res 2:153-155, 1992
12. Meyskens FL Jr, Voakes JB: Tamoxifen in malignant melanoma. Cancer Treat Rep 64:171-173, 1980
13. Chary KK, Higby DJ, Henderson ES, et al: Phase I study of high-dose cisdichlorodiamenplatinum (II) with forced diuresis. Cancer Treat Rep 61:367-370, 1977
14. Goodnight JE Jr, Moseley HS, Eilber FR, et al: Cisdichlorodiamenplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 63:2005-2007, 1979
15. Friedman MA, Kaufman DA, Williams JE, et al: Combined DTIC and cisdichlorodiamenplatinum (II) therapy for patients with disseminated melanoma: A Northern California Oncology Group study. Cancer Treat Rep 63:493-495, 1979
16. Fletcher WS, Green S, Fletcher JR, et al: Evaluation of cisplatinum and DTIC combination chemotherapy in disseminated melanoma. Am J Clin Oncol 11:589-593, 1988
17. Oratz R, Speyer JL, Green M, et al: Treatment of metastatic malignant melanoma with dacarbazine and cisplatin. Cancer Treat Rep 71:877-878, 1987
18. Del Prete SA, Maurer LH, O'DonnelI J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
19. McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
20. Richards JM, Gilewski TA, Doane LL, et al: Active chemotherapy for metastatic melanoma following failure of interleukin-2-based therapy. Proc Am Assoc Cancer Res 31:199, 1990 (abstr 1186)
21. McClay EF, Mastrangelo MJ, Bellet RE, et al: An effective chemo/hormonal therapy regimen for the treatment of disseminated malignant melanoma. Update I. Proc Am Soc Clin Oncol 8:282, 1989 (abstr 1098)
22. Berd D, McLaughlin CJ, Hart E, et al: Short course, high dose tamoxifen with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 10:291, 1991 (abstr 1016)
23. Buzaid AC, Murren JR, Durivage HJ: High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 68:1238-1241, 1991
24. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
25. Guerry D IV, Schuchter LM: Disseminated melanoma - Is there a new standard therapy? N Engl J Med 327:560-561 1992
26. Fleming T: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
27. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
28. Murren JR, DeRosa W, Durivage HJ, et al: High-dose cisplatin plus DTIC in the treatment of metastatic melanoma. Cancer 67:1514-1517, 1991
29. Lattanzi SC, Tosteson T, Maurer LH, et al: Dacarbazine (D), cisplatin (C), carmustine (B) ± tamoxifen (T) in the treatment of patients with metastatic melanoma: Results of 5-year follow-up. Proc Am Soc Clin Oncol 12:390, 1993 (abstr 1333)
30. Ferri W, Kirkwood JM, Vlock D, et al: Carboplatin (C) and dacarbazine (D) ± tamoxifen (T) for metastatic melanoma. Proc Am Soc Clin Oncol 12:396, 1993 (abstr 1358)
31. McClay EF, Christen R, Albright KA, et al: Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52:6790-6796, 1992
32. McClay EF, Albright KA, Jones JA, et al: Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53:1571-1576, 1993
33. Verschraegen CF, Kleeberg UR, Mulder J, et al: Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma: A phase II study of the EORTC Malignant Melanoma Cooperative Group. Cancer 62:1061-1065, 1988
34. McClay EF, McClay ET: Tamoxifen: Is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12:617-626, 1994